SciVision Biotech

SciVision Biotech Equity

The The Equity of SciVision Biotech (1786.TW) as of Nov 2, 2026 is 1.98 B TWD. In the previous year, The Equity was 1.90 B TWD — a change of 4.38% (higher).

Equity

1.98 BTWD

YoY

4.38%

Last updated:

In 2025, SciVision Biotech's equity was 1.98 B TWD, a 4.38% increase from the 1.90 B TWD equity in the previous year.

The SciVision Biotech Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
1.08 B TWD
Jan 1, 2019
1.36 B TWD
Jan 1, 2020
1.40 B TWD
Jan 1, 2021
1.45 B TWD
Jan 1, 2022
1.51 B TWD
Jan 1, 2023
1.63 B TWD
Jan 1, 2024
1.90 B TWD
Jan 1, 2025
1.98 B TWD
The SciVision Biotech Equity history
YEAREquityYoY
1.98 BTWD+4.38%
1.90 BTWD+16.63%
1.63 BTWD+7.65%
1.51 BTWD+4.21%
1.45 BTWD+3.25%
1.40 BTWD+3.19%
1.36 BTWD+26.22%
1.08 BTWD+17.89%
914.45 MTWD+2.26%
894.21 MTWD-5.73%
948.60 MTWD-7.28%
1.02 BTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

SciVision Biotech Stock analysis

What does SciVision Biotech do? SciVision Biotech Inc, based in Kaohsiung, Taiwan, specializes in the research, development, and production of hyaluronic acid medical products. The company offers subcutaneous fillers for plastic surgery, joint cavity injections for orthopedics, and hyaluronic acid raw materials. It also provides DNA identification, detection, sequencing, and related applications, alongside care products and food manufacturing. SciVision Biotech operates globally across the Americas, Europe, Asia, the Middle East, and Africa. SciVision Biotech is one of the most popular companies on Eulerpool.

Equity Details

Analyzing SciVision Biotech's Equity

SciVision Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding SciVision Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating SciVision Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

SciVision Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in SciVision Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about SciVision Biotech stock

The Equity of SciVision Biotech is 1.98 B TWD in 2025.

The Equity of SciVision Biotech changed from 1.90 B TWD to 1.98 B TWD, representing a 4.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity SciVision Biotech since 2006 – with annual values, charts, and detailed analysis.

The Equity's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's SciVision Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — SciVision Biotech

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — SciVision Biotech